Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VK2735

Peptide · Agonist of GLP-1 receptor (GLP1R) and GIP receptor (GIPR) · developed by Viking Therapeutics

Phase 3 Most advanced trial

VKTX Developer

2 Registered trials

What is VK2735?

VK2735 is a peptide dual agonist of the GLP-1 and GIP receptors. It is administered subcutaneously or orally in various dosing schedules. The drug is being studied for weight loss in obese adults.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Targets: GLP-1 receptor (GLP1R), GIP receptor (GIPR)
Mechanism: Agonist of GLP-1 receptor (GLP1R) and GIP receptor (GIPR)
Pathways: cAMP signaling, glucose homeostasis
Therapy area: Endocrine
Developer: Viking Therapeutics, Inc. (VKTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07104500	Phase 3	Weight Loss	Active not recruiting	VKTX
NCT07838740	Phase 1	Obese Adults	Recruiting	VKTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obese AdultsWeight Loss

Other drugs acting on GLP1R / GIPR

Dulaglutide FDA approved Orforglipron FDA approved Semaglutide FDA approved Tirzepatide FDA approved Avexitide Phase 3 DehydraTECH-semaglutide Phase 1 LY3537021 Phase 2 Maridebart Cafraglutide Phase 3

More from Viking Therapeutics

VK0214 Investigational VK2809 Investigational VK5211 Investigational

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VKTX page.

Follow VKTX, the company behind VK2735

See VKTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VKTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z